Hoekstra J, Cohen M
Department of Emergency Medicine, Wake Forest University Health Science, Winston-Salem, NC, USA.
Int J Clin Pract. 2009 Apr;63(4):642-55. doi: 10.1111/j.1742-1241.2009.01998.x. Epub 2009 Feb 13.
In 2007, the American College of Cardiology/American Heart Association (ACC/AHA) published new guidelines for the diagnosis and management of patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI). These guidelines include some important updates on the use of clopidogrel, fondaparinux, bivalirudin and low-molecular-weight heparins (LMWHs) all of which have published landmark clinical trials in patients with acute coronary syndromes (ACS) since the publication of the 2002 guidelines. While these 2007 guidelines are more comprehensive and up-to-date compared with the recommendations published in 2002, they also raise many questions for practising emergency physicians and cardiologists.
This article presents a critical review of the 2007 ACC/AHA UA/NSTEMI guidelines, highlighting some of the areas of controversy, with the aim of providing some further guidance to practising physicians.
Despite recent updates to the ACC/AHA UA/NSTEMI guidelines, additional factors need to be taken into consideration in the management of UA/NSTEMI patients. Integrating initial responses with early or selectively invasive strategies and the risks of complications in subsequent procedures require careful consideration. Protocol development within an institution is required to risk-stratify patients rapidly, provide optimum precatheterisation medical management and allow seamless and rapid transitions to the catheterisation laboratory in patients at risk for adverse events.
2007年,美国心脏病学会/美国心脏协会(ACC/AHA)发布了不稳定型心绞痛/非ST段抬高型心肌梗死(UA/NSTEMI)患者诊断和管理的新指南。这些指南包括氯吡格雷、磺达肝癸钠、比伐卢定和低分子肝素(LMWHs)使用方面的一些重要更新,自2002年指南发布以来,所有这些药物均已在急性冠状动脉综合征(ACS)患者中发表了具有里程碑意义的临床试验。虽然这些2007年的指南比2002年发布的建议更全面、更新,但它们也给执业急诊医师和心脏病专家提出了许多问题。
本文对2007年ACC/AHA UA/NSTEMI指南进行了批判性综述,突出了一些存在争议的领域,旨在为执业医师提供一些进一步的指导。
尽管ACC/AHA UA/NSTEMI指南最近有更新,但在UA/NSTEMI患者的管理中还需要考虑其他因素。将初始反应与早期或选择性侵入性策略以及后续手术并发症的风险相结合需要仔细考虑。机构内需要制定方案,以便对患者进行快速风险分层,提供最佳的导管插入术前医疗管理,并使有不良事件风险的患者能够无缝、快速地转至导管插入实验室。